Trial marks key milestone in driving pipeline progress
Phase 1 trial scheduled for completion mid-June 2025
Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to support an accelerated approval, subject to FDA feedback
Read MoreKey Regulatory Milestone Provides Clear Development Roadmap to Registration for MOTYS
Initiation of Phase 3 Program Remains on Schedule to Begin in Q3 2025
Company Updates Investor Presentation to Reflect Strong Q1 Earnings, More than $20M in Pro Forma Revenue and 15% Increase in 2025 Pro Forma Revenue Guidance
Read More
The appearance of Thomas Prevoznik and Matthew Strait as thought leaders in global drug policy is more than just tone-deaf-it's dangerous. It validates a failed regulatory approach that punishes innovation, undermines public health, and sidelines scientific progress for political convenience
Read More
AGFA HealthCare earns top-tier recognition for consistently delivering high-value imaging management solutions and services to healthcare organizations of all sizes.
Read MoreCrossTx Inc., a national leader in Medicare care management solutions, is proud to announce a strategic partnership with EverCare Mobile Health, Idaho's fast-growing mobile mental healthcare provider serving long-term care facilities across the region.
Read MoreEarly results show steroid-free remission, opening pathway into $13B global pet dental health market
VELDONA delivers consistent anti-inflammatory effects, strengthening Ainos' positioning in companion animal immunotherapy
Read MoreCompany reports quarterly revenue of $1.4 million; net loss and earnings per diluted Share of $6.6 million and $1.74
Quarterly adjusted EBITDA loss of $2.5 million reflects 29% YOY improvement
Stockholders' equity was $13.8 million at quarter end
Increases 2025 pro forma revenue guidance to more than $75 million based on strong first quarter across TRNR, Sportstech and Wattbike
Read More
"The DEA is creating a regulatory paradox where science is stifled and illegal activity is tolerated. Thomas Prevoznik, one unelected bureaucrat should not have the power to derail federally authorized drug development," said Duane Boise, CEO of MMJ International Holdings.
Read MoreThe combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4 million and 37% versus net Q4 2024 revenue of $3.5 million
Mytesi prescription volume increased by approximately 1.8% in Q1 2025 over Q1 2024 and decreased by approximately 13.5% in Q1 2025 over Q4 2024
REMINDER: Today Jaguar to host investor webcast at 4:15 p.m. Eastern regarding Q1 2025 financials and company updates; Click here to register
Proof-of-concept (POC) results show crofelemer reduced total parenteral nutrition in patients with rare orphan diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) by up to 27% and 12.5% - potential to modify disease progression in intestinal failure patients; Click here to access replay of April 30, 2025 investor webcast about results; additional POC results expected throughout 2025 for MVID and SBS-IF
FDA meeting in Q2 2025 on statistically significant results of Phase 3 OnTarget trial of crofelemer in prespecified subgroup of patients with breast cancer
Read More
9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials
Mipletamig triplet combination continues to outperform standard doublet benchmark
No cytokine release syndrome observed in the ongoing RAINIER trial: favorable safety profile supports role in frontline AML
Cohort 2 enrollment is complete, and Cohort 3 is now enrolling
Read MoreAntimicrobial resistance is recognized as one of the top global public health threats, and Telomir-Ag2 strengthens Telomir's pipeline with a differentiated candidate designed to address this urgent and expanding crisis
Read More
Duane Boise MMJ CEO stated "At the center of the MMJ cannabis pharmaceutical litigation sits DEA Thomas Prevoznik, an unearthed official with no medical or scientific expertise, who wields unchecked power to deny therapies under the guise of public safety."
Read More
69% Blame Poor EHR Usability for Job Dissatisfaction, 80% Consider Nurse-Friendly Systems When Job Hunting, and 2 in 3 Nurses Under 40 Say EHR Experience Impacts Employer Choice - Black Book's Sweeping 8-Month Survey Finds
Read More
Collaboration unites SumHealth's healthcare industry expertise and BenchMarks analytics tool with Gigasheet's powerful data processing platform to deliver unprecedented access to hospital and payer real-world healthcare prices.
Read More- Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints -
- Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY® for the treatment of axillary hyperhidrosis -
- Raised $8.8 million in gross proceeds from private placement and warrant inducement financings during the first quarter of 2025 -
Read MoreExpanding Beyond Gummies, Gummi World Launches Capsule Manufacturing to Deliver Full-Spectrum, Clinically Backed Supplement Solutions - Faster, Cleaner and All Under One Roof
Read More
